Product Information
CYMBALTA 20 MG CAPSULE is a brand product labeled by Eli Lilly and Company, priced at $7.9836 per EA under NDC 00002323560. Its NADAC has been published 312 times since Nov 28, 2013.
FDA first approved this application on Aug 3, 2004.
The High Outlier badge above means this manufacturer's average price in the Duloxetine hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
20 mg/1
Manufacturer
Eli Lilly and CompanyNDC
00002323560
Classification
Brand
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Effective Date
7/23/2025
Active Ingredients
DULOXETINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA021427FDA Approved
8/3/2004
On Market Since
8/24/2004
Pharmacological Classes
Price Statistics
The NADAC for CYMBALTA 20 MG CAPSULE has been published 312 times since Nov 28, 2013, and over the history we have for it it has risen 27.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.9836 per EA |
|---|---|
| All-time high | $8.0748 (Apr 10, 2024) |
| All-time low | $6.2561 (May 21, 2014) |
| 52-week high | $7.9836 |
| 52-week low | $7.9836 |
| Median price | $7.9836 |
| Average price | $7.2371 |
| Largest weekly change | +27.3% (Apr 19, 2023) |
| Weeks tracked | 312 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
0.0%
6M
0.0%
1Y
0.0%
3Y
-1.1%
5Y
+25.8%
All
+27.2%
Last surveyed Jul 15, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Duloxetine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Duloxetine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CYMBALTA 20 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CYMBALTA 20 MG CAPSULE, manufactured by Eli Lilly and Company, is $7.9836 per EA (NDC 00002323560), effective Jul 15, 2026.
How has the price of CYMBALTA 20 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CYMBALTA 20 MG CAPSULE has risen 27.2%. It has been tracked across 312 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CYMBALTA 20 MG CAPSULE?
Since Nov 28, 2013, the NADAC for CYMBALTA 20 MG CAPSULE has ranged from a low of $6.2561 (May 21, 2014) to a high of $8.0748 (Apr 10, 2024), with a median of $7.9836 per EA.
Are there cheaper alternatives to CYMBALTA 20 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of CYMBALTA 20 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CYMBALTA 20 MG CAPSULE?
CYMBALTA 20 MG CAPSULE (NDC 00002323560) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.